The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
about
The new oral anticoagulants and the future of haemostasis laboratory testingMetalloproteases Affecting Blood Coagulation, Fibrinolysis and Platelet Aggregation from Snake Venoms: Definition and Nomenclature of Interaction SitesArgatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.Bivalirudin as an adjunctive anticoagulant to heparin in the treatment of heparin resistance during cardiopulmonary bypass-assisted cardiac surgery.Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trialHypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsStroke prevention in atrial fibrillation: concepts and controversiesA semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experiencePharmacological Therapy in Stroke Prophylaxis - The New versus the Old AgentsLaboratory assessment of new anticoagulants.Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.Acute stroke management in patients taking dabigatran.Acute management of bleeding in patients on novel oral anticoagulants.Monitoring target specific anticoagulants.Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.Dabigatran: is there a role for coagulation assays in guiding therapy?Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.Modifications of natural peptides for nanoparticle and drug design.Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.Laboratory measurement of the direct oral anticoagulants.Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise.In vivo evaluation of homeostatic effects of Echis carinatus snake venom in IranAssessment of the Antimicrobial Activity of Few Saudi Arabian Snake Venoms.Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.Measuring Direct Oral Anticoagulants.The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG®), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT).β2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions.Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study.
P2860
Q27022461-3E4BE408-0644-4353-8542-D1174A203D6AQ28075348-FD665AF0-22B1-416F-BA03-BC49094C49EBQ33370696-AC2D7619-7D30-4DC8-BA6A-1012B479F5D2Q33422490-D4600606-85C2-4681-9902-756866CD583CQ33427441-55E154FF-D7DE-4AD2-8294-1DFFA9385EB8Q33875897-8105F99E-2A2D-48B1-843E-E0259A3A6910Q35154142-4468E770-CB94-449B-8638-D0E0393036B1Q35674404-D88DAE19-A129-4E15-A356-0142DEC49CE0Q36382375-1D7A7881-4380-4030-819B-B8E665DC312AQ36988011-F711AD96-1A60-4DC2-9C31-553617A2F2BCQ37246953-BF637592-38F3-437C-8553-2399C6C21F1AQ37495788-E289DAA1-EA51-4405-83D0-72A8598348BCQ37834646-9AE69EB6-96EE-484B-B07A-FF01AFD735DDQ37900217-ABB4256D-15B9-47F0-8908-FE191E6CADB2Q37924500-8236D9F3-571F-4E07-BBDA-4E675F1B062AQ38005465-2263E334-F7A0-40F8-B058-1F30B23261CCQ38065699-E9697767-5F9B-4E6A-8B7C-727288176B2DQ38079153-51E8B650-7CBF-4A6B-9228-29379BCBE7D8Q38091327-C4E59A41-A0A2-4827-968A-37C9938DEF0CQ38106596-51084DA9-4423-4C64-AAF0-FDD0E0743AB1Q38106833-8F007499-6536-48B9-B0D1-50479E11DB88Q38118482-92FB2036-50DC-4FA4-B596-716059DB922AQ38132255-24B812FB-5D11-4632-8FA0-A86F2B1B2345Q38369494-F3485701-B508-47AC-9D3F-139489B9B242Q38608242-BE4A29B5-9D4B-460C-A5B9-92B11FAEA3FBQ38613869-D333C348-54EE-4597-B75A-F946A37A6E70Q39149214-28C04001-6A56-41C0-AB7B-AB9C9CE3BB4FQ41869474-89E1E824-47F0-4A90-9342-FE09CD7454B9Q42012466-F4ACE90A-E150-45AB-9CC1-224FE1F6F713Q45874001-FD0B8294-F10C-41D2-BAF6-6D3C41C08313Q46578398-197E2D2C-B1EA-466B-BCBA-4C2BBBDD23F6Q47204779-FB2A73D9-1CAE-4F14-8948-340707E95191Q51074186-3D1306B4-3E11-4A07-A4D0-29EC81C48474Q51392267-64E92800-D51A-456C-8B76-82EBDA156182
P2860
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@ast
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@en
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@nl
type
label
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@ast
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@en
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@nl
prefLabel
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@ast
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@en
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@nl
P2860
P3181
P356
P1476
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
@en
P2093
Götz Nowak
P2860
P304
P3181
P356
10.1159/000081505
P407
P577
2003-01-01T00:00:00Z